Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 3/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093406 | 0.86 | RIPK1 (0.42) | USP30HTR2CSLC6A4CXCR2AAK1 | |
| SCHEMBL26463101 | 0.85 | USP30 (0.39) | USP30CXCR2AAK1BACE1BACE2 | |
| SCHEMBL21903279 | 0.85 | HTR2C (0.39) | USP30HTR2CSLC6A4AAK1BACE1 | |
| SCHEMBL774040 | 0.84 | USP30 (0.38) | USP30CXCR2AAK1BACE1BACE2 | |
| SCHEMBL8152018 | 0.83 | ITGA4 (0.37) | USP30HTR2CSLC6A4BACE1BACE2 | |
| SCHEMBL23536625 | 0.83 | CXCR2 (0.39) | CXCR2RIPK1 | |
| SCHEMBL23563489 | 0.82 | BACE1 (0.38) | USP30HTR2CSLC6A4AAK1BACE1 | |
| SCHEMBL30013628 | 0.82 | BACE1 (0.38) | USP30HTR2CSLC6A4AAK1BACE1 | |
| SCHEMBL29799702 | 0.82 | PTGDR2 (0.40) | CXCR2 | |
| SCHEMBL27186377 | 0.82 | PTGDR2 (0.40) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230312482-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312482-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4097084-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115052860-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022026465-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021154902-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312482-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | USP30 1179/4885HTR2C 4431/4885SLC6A4 3176/4885 |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | USP30 1193/4885HTR2C 4619/4885SLC6A4 1732/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | USP30 849/4885HTR2C 4269/4885SLC6A4 3716/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | USP30 1179/4885HTR2C 4431/4885SLC6A4 3176/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | USP30 849/4885HTR2C 4269/4885SLC6A4 3716/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | USP30 1179/4885HTR2C 4431/4885SLC6A4 3176/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | USP30 1179/4885HTR2C 4431/4885SLC6A4 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.